Is there neuroprotection in Parkinson syndrome?

Journal of Neurology, Supplement

Volumn 247, Issue 4, 2000, Pages 8-11

  Riederer, P ^a   Sian, J ^a   Gerlach, M ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Dopamine agonists; MAO B inhibitors; Neuroprotection; NMDA receptor antagonists; Parkinson's disease

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; ROPINIROLE;

DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; NEUROPROTECTION; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; HUMANS; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; RECEPTORS, N-METHYL-D-ASPARTATE; SELEGILINE; VITAMIN E;

EID: 0033811763     PISSN: 09391517     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Brain dopamine and the syndrome of Parkinson and Huntington: Clinical, morphological and neurochemical correlations
2. Responsibility of extrastriatal areas for the appearance of psychotic symptoms
3. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: A long term study
4. Pathoanatomy of Parkinson's disease
5. Significance of neuromelanin for neurodegeneration in Parkinson's disease
6. Is levodopa toxic?
7. Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson's disease
8. A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurones in basal ganglia-thalamocortical circuits in Parkinson syndrome
9. Molecular mechanisms of neurodegeneration: Synergism between reactive oxygen species, calcium and excitotoxic amino acids
10. Pharmacology of selegiline
11. The possible role of nitric oxide in the pathogenesis of Parkinson's disease
12. Time sequences of dopaminergic cell death in Parkinson's disease: Indications for neuroprotective studies
13. Preclinical and clinical aspects of Dopamine agonists. What is known for certain?
14. Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostratal projections and differential neuron susceptibility in Parkinson's disease
15. Glial cells and Parkinson's disease
16. Pathophysiology and biochemistry of dyskinesia: Clues for the development of non-dopaminergic treatments
17. Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex
18. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: A human postmortem brain study
19. Evidence for active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure
20. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early mild Parkinson's disease
21. Effect of adding selegiline to levodopa in early, mild Parkinson's disease
22. 18F]dopa PET study
23. Nigral degeneration in Parkinson's disease in relation to clinical features
24. Reduced intravenous glutathione in the treatment of early Parkinson's disease
25. Modulation of gene expression rather than monoamine oxidase inhibition: (-) Deprenyl-related compounds in controlling neurodegeneration
26. Therapeutic potential of neurotrophic factors for neurological disorders